Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical — Corporate Update (December 2018)
15 slides from Biohaven Pharmaceutical's corporate update, Dec 3, 2018
Slide 1: Advancing Innovative Therapies for Neurological Diseases: Phase 3 Topline Rimegepant 75 mg Zydis ODT
December 03, 2018 Advancing Innovative Therapies for Neurological Diseases Phase 3 Topline Rimegepant 75 mg Zydis ODT
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about our plans to develop and commercialize our product candidates, the timing of our planned regulatory fil
Slide 3: Advancing Multiple Treatments and Formulations for Acute and Preventive Treatment of Migraine
Advancing Multiple Treatments and Formulations, Meeting Patient Needs for Acute and Preventive Treatment of Migraine DECEMBER 2018 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES * Exclusive World-Wide License with Catalent for use of Zydis® Fast Dissolve Technology in our migraine product
Slide 4: Phase 3 Topline Summary from Study in the Acute Treatment of Migraine
Rimegepant 75 mg Zydis ODT Phase 3 Topline Summary from Study 303 in the Acute Treatment of Migraine
Slide 5: Positive Phase 3 Results with Rimegepant Zydis ODT
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Profile of Rapid & Lasting Benefit in the Acute Treatment of Migraine DECEMBER 2018 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES A
Slide 6: Trial Design for Pivotal Phase 3 Study 303
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT DECEMBER 2018 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES Study 303 used similar design as previous Studies 301 and 302 1375 subjects treated 682 rimegepant 693 placebo Demographics were representative of typi
Slide 7: Demographics for Rimegepant Zydis ODT Study 303
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT Demographics for Rimegepant Zydis ODT Study 303: Trial is Representative of Typical Migraine Patient Population Patient Demographics and Migraine History Female > Male (~85% F; 15% M) Average age = ~39 years old Diverse pa
Slide 8: Successful Achievement of Both Regulatory Co-Primary Endpoints
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT Successful Achievement of Both Regulatory Co-Primary Endpoints: Pivotal Phase 3 Trial of Rimegepant 75 mg Zydis ODT 1. Most Bothersome Symptom of Photophobia, Phonophobia or Nausea. DECEMBER 2018 ADVANCING INNOVATIVE THERA
Slide 9: Increasing Benefit Over Time on Pain Freedom After Single Dose
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT Increasing Benefit Over Time on Pain Freedom After Single Dose of Rimegepant 75 mg Zydis ODT Formulation DECEMBER 2018 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES Single Dose of Rimegepant, No Rescue Meds % of
Slide 10: Pain Relief: Early Separation and Continued Improvement
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT Pain Relief1: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications for Rimegepant 75 mg Zydis ODT Kaplan-Meier Curve of Time to Pain Relief up to 2 Hours Post Single Dose1 Single Dose
Slide 11: Pooled Adverse Event Safety Data
RIMEGEPANT (BHV-3000) Phase 3 studies – 301, 302 (75 mg Tablet) & 303 (75 mg Zydis ODT) Pooled Adverse Event (AE) Safety Data: Rimegepant was Well Tolerated and Similar to Placebo Across Studies AEs from Studies 301, 302 and 303 with an incidence > 1% Adverse Event Rimegepant N=1771 Placebo N=1785 >
Slide 12: Pooled Liver Function Test Profile
RIMEGEPANT (BHV-3000) Phase 3 studies – 301, 302 (75 mg Tablet) & 303 (75 mg Zydis ODT) Pooled Liver Function Test (LFT) Profile: Rimegepant Liver Safety was Similar to Placebo Across Studies ALT or AST Rimegepant N=1771 Placebo N=1785 > ULN 2 48 (2.7%) 52 (2.9%) > 3x ULN 2 (0.1%) 2 (0.1%) > 5x ULN
Slide 13: Summary: Positive Phase 3 Results with Rimegepant Zydis ODT
RIMEGEPANT (BHV-3000) Phase 3 TOPLINE – Study 303, rimegepant 75 mg ZYDIS ODT Summary: Positive Phase 3 Results with Rimegepant Zydis® ODT – Profile of Rapid and Lasting Benefit in the Acute Treatment of Migraine DECEMBER 2018 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES Rapid onset of p
Slide 14: Q&A
Rimegepant (BHV-3000) 75 mg Zydis ODT Phase 3 Topline Small Molecule CGRP Receptor Antagonist Q&A
Slide 15: Thank You!
Thank You! www.biohavenpharma.com
Biohaven Pharmaceutical Holding — Corporate Update (December 2018) on 6ix